Validation of Mood Measures for People with Multiple Sclerosis

Watson, Tessa M.; Ford, Emma; Worthington, Esme; Lincoln, Nadina B.

doi:10.7224/1537-2073.2013-013

Cited by 85 publications

(102 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This notion is supported by a recent study which has found that the HADS and Beck Inventories may not be valid measures of psychiatric illness in OP-exposed participants (Harrison & Mackenzie Ross, under review); nor in many other patient groups with concurrent ill-health symptoms (e.g. Golden et al, 2007;Mitchell et al, 2010;Poole et al, 2006;Watson et al, 2014). Thus it is unclear how meaningful the information derived from self-report measures is in clinical, or real-world terms.…”

Section: Discussionmentioning

confidence: 99%

“…Although self-report measures may be useful for screening purposes in large populations, it is not always clear whether findings are comparable with what would be derived from structured clinical interviews undertaken by mental health professionals using internationally agreed diagnostic criteria for mental disorders. Indeed, previous research with other patient cohorts (including multiple sclerosis, cancer, cardiomyopathy, hepatitis C) has shown that self-report measures may not be good indictors of psychiatric disorder (Golden et al, 2007;Mitchell et al, 2010;Poole et al, 2006;Watson et al, 2014), and a recent study suggests this may be particularly true for research with OP exposed groups (Harrison & Mackenzie Ross, under review). Structured interviews standardise the coverage of specific psychiatric issues (thus reducing the possibility of missed diagnoses) and require the systematic appraisal of relevant symptoms, to reduce misdiagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anxiety and depression following cumulative low-level exposure to organophosphate pesticides

Harrison

Ross

2016

Environmental Research

View full text Add to dashboard Cite

Previous research suggests that individuals with a prior history of pesticide poisoning are at increased risk of psychiatric disorder (Freire & Koifman, 2013), but findings regarding the impact of cumulative low-level exposure are inconsistent. The aim of the current study was to investigate whether sheep farmers with a history of low-level exposure to organophosphate pesticides (1) report a higher level of psychological distress on subjective symptom questionnaires, compared to unexposed controls (2) also meet internationally agreed diagnostic criteria for a psychiatric disorder more often than unexposed controls. 127 sheep farmers were evaluated and compared to 78 unexposed controls, matched in terms of gender, education, level of intelligence, working status and area of residence. Both self-report measures and structured clinical interviews were used to assess mental health. The exposed cohort reported significantly higher rates of anxiety and depression when self-report questionnaires were used to evaluate mood, even when stressful life events, demographic and physical health factors were taken into account. However, when diagnostic interviews were used to assess mood, this pattern only held true for anxiety.3

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anxiety and depression following cumulative low-level exposure to organophosphate pesticides

Harrison

Ross

2016

Environmental Research

View full text Add to dashboard Cite

show abstract

“…Owing to the heterogeneity of included studies (n = 4) with respect to the HADS-A had a sensitivity of 90% and a specificity of 92% compared with the SCAN. 21 This cut-point produced a positive predictive value of 82%, a negative predictive value of 96%, and an AUC of 0.94 for any anxiety disorder. 21 Compared with the BAI (cut-point ≥16), the HADS-A with a cut-point of 7 had a sensitivity of 71% and a specificity of 63%, which was the optimal cut-point according to ROC analyses.…”

Section: Resultsmentioning

confidence: 99%

“…21 This cut-point produced a positive predictive value of 82%, a negative predictive value of 96%, and an AUC of 0.94 for any anxiety disorder. 21 Compared with the BAI (cut-point ≥16), the HADS-A with a cut-point of 7 had a sensitivity of 71% and a specificity of 63%, which was the optimal cut-point according to ROC analyses. 22 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Screening Tools for Anxiety in People with Multiple Sclerosis

Litster¹,

Fiest²,

Patten³

et al. 2016

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis

Mohseni

Hosseini

Majdinasab

et al. 2023

Neuropsychopharm Rep

View full text Add to dashboard Cite

AimN‐acetylcysteine (NAC), a thiol‐containing antioxidant and glutathione (GSH) precursor, attenuates oxidative stress, and possibly improves psychiatric disorders. This study aimed to evaluate the effects of oral NAC on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).MethodsThis clinical trial was conducted on 42 MS patients randomly assigned to intervention (n = 21) and control (n = 21) groups. The intervention group received 600 mg of NAC twice daily for 8 weeks, and the control group received a placebo with the same prescription form. An analysis of serum malondialdehyde (MDA), serum nitric oxide (NO), and erythrocyte GSH was carried out on both groups, along with a complete blood count. The Hospital Anxiety and Depression Scale (HADS) was used to assess symptoms of depression (HADS‐D) and anxiety (HADS‐A).ResultsCompared to the control group, NAC consumption significantly decreased serum MDA concentrations (−0.33 [−5.85–2.50] vs. 2.75 [−0.25–5.22] μmol/L; p = 0.03) and HADS‐A scores (−1.6 ± 2.67 vs. 0.33 ± 2.83; p = 0.02). No significant changes were observed in serum NO concentrations, erythrocyte GSH levels, and HADS‐D scores (p > 0.05).ConclusionsBased on the findings of the present study, NAC supplementation for 8 weeks decreased lipid peroxidation and improved anxiety symptoms in MS patients. The aforementioned results suggest that adjunctive therapy with NAC can be considered an effective strategy for MS management. Further randomized controlled studies are warranted.

show abstract

Validation of Mood Measures for People with Multiple Sclerosis

Abstract: Background: Valid assessments are needed in order to identify anxiety and depression in people with multiple sclerosis (MS). The objective of this study was to assess the validity of questionnaire measures of mood in people with MS.

Cited by 85 publications

References 21 publications

Anxiety and depression following cumulative low-level exposure to organophosphate pesticides

Anxiety and depression following cumulative low-level exposure to organophosphate pesticides

Screening Tools for Anxiety in People with Multiple Sclerosis

Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis

Contact Info

Product

Resources

About